|
GB8311018D0
(en)
|
1983-04-22 |
1983-05-25 |
Amersham Int Plc |
Detecting mutations in dna
|
|
US4998617A
(en)
|
1986-09-15 |
1991-03-12 |
Laura Lupton Inc |
Facial cosmetic liquid make up kit
|
|
US6270961B1
(en)
|
1987-04-01 |
2001-08-07 |
Hyseq, Inc. |
Methods and apparatus for DNA sequencing and DNA identification
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
FR2650840B1
(fr)
|
1989-08-11 |
1991-11-29 |
Bertin & Cie |
Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
US6004744A
(en)
|
1991-03-05 |
1999-12-21 |
Molecular Tool, Inc. |
Method for determining nucleotide identity through extension of immobilized primer
|
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
|
US5952172A
(en)
|
1993-12-10 |
1999-09-14 |
California Institute Of Technology |
Nucleic acid mediated electron transfer
|
|
US5968740A
(en)
|
1995-07-24 |
1999-10-19 |
Affymetrix, Inc. |
Method of Identifying a Base in a Nucleic Acid
|
|
WO1997040462A2
(en)
|
1996-04-19 |
1997-10-30 |
Spectra Biomedical, Inc. |
Correlating polymorphic forms with multiple phenotypes
|
|
JP2894445B2
(ja)
|
1997-02-12 |
1999-05-24 |
日本たばこ産業株式会社 |
Ｃｅｔｐ活性阻害剤として有効な化合物
|
|
CA2303206A1
(en)
|
1997-09-10 |
1999-03-18 |
University Of Maryland, Baltimore |
Method of amplifying dna and rna mismatch cleavage products
|
|
US6197786B1
(en)
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
|
WO2000074471A1
(en)
|
1999-06-04 |
2000-12-14 |
Consejo Superior De Investigaciones Cientificas |
Use of high oleic high stearic oils
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
CO5271716A1
(es)
|
1999-11-30 |
2003-04-30 |
Pfizer Prod Inc |
Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
|
|
AU2002323270A1
(en)
|
2001-08-18 |
2003-03-03 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
|
US20060141493A1
(en)
|
2001-11-09 |
2006-06-29 |
Duke University Office Of Science And Technology |
Atherosclerotic phenotype determinative genes and methods for using the same
|
|
WO2004067763A2
(en)
|
2003-01-27 |
2004-08-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetic diagnosis of alcoholism subtypes
|
|
JP2006520810A
(ja)
|
2003-03-17 |
2006-09-14 |
日本たばこ産業株式会社 |
Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
|
|
TWI393560B
(zh)
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
EP1644335A4
(en)
|
2003-07-11 |
2008-06-04 |
Bristol Myers Squibb Co |
TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
|
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
|
EP2319509A1
(en)
|
2003-09-26 |
2011-05-11 |
Japan Tobacco, Inc. |
Method of Inhibiting remnant lipoprotein production
|
|
EP1670460B1
(en)
|
2003-10-10 |
2014-11-26 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
PT1697370E
(pt)
|
2003-12-19 |
2007-05-31 |
Bristol Myers Squibb Co |
Heterociclos azabicíclicos como moduladores do receptor de canabinóides
|
|
PT1697371E
(pt)
|
2003-12-19 |
2007-08-03 |
Bristol Myers Squibb Co |
Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
|
|
JP2007531769A
(ja)
|
2004-03-30 |
2007-11-08 |
サファイア セラピューティクス インコーポレイテッド |
成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
|
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
WO2006063828A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
|
|
CA2593793A1
(en)
|
2005-01-05 |
2006-07-13 |
Medicure International Inc. |
Compounds and methods for regulating triglyceride levels
|
|
WO2006099142A2
(en)
*
|
2005-03-10 |
2006-09-21 |
The Trustees Of Boston University |
Prognostic method for vascular diseases
|
|
JP2006288279A
(ja)
|
2005-04-11 |
2006-10-26 |
Otsuka Pharmaceut Co Ltd |
出血時間延長傾向判定方法
|
|
AU2006265975B2
(en)
|
2005-07-01 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Process for synthesizing a CETP inhibitor
|
|
AU2006304836A1
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
|
US7435849B2
(en)
|
2005-10-31 |
2008-10-14 |
Hoffmann-La Roche Inc. |
Process for the production of acid chlorides
|
|
JP2009514851A
(ja)
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
|
US20070213274A1
(en)
*
|
2005-12-20 |
2007-09-13 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
EP1935867A1
(en)
|
2006-12-20 |
2008-06-25 |
F. Hoffmann-La Roche Ag |
Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
|
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
ES2395167T3
(es)
|
2007-04-25 |
2013-02-08 |
F. Hoffmann-La Roche Ag |
Nuevo proceso para la obtención de cloruros de ácido
|
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
JP5564487B2
(ja)
|
2008-04-04 |
2014-07-30 |
エフ．ホフマン−ラ ロシュ アーゲー |
シクロヘキサンカルボン酸誘導体の新規な製造方法
|
|
JP5526120B2
(ja)
|
2008-04-04 |
2014-06-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
対応するシクロヘキサンカルボキシアミド誘導体を経るシクロヘキサンカルボン酸誘導体の新規な製造方法
|
|
WO2009153181A1
(en)
|
2008-06-17 |
2009-12-23 |
F. Hoffmann-La Roche Ag |
1-(2-ethyl-butyl) -cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
US20100183598A1
(en)
|
2008-11-12 |
2010-07-22 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
AU2009326326B2
(en)
|
2008-12-08 |
2015-05-21 |
F. Hoffmann-La Roche Ag |
Combined drug administration
|
|
MX2011011517A
(es)
|
2009-04-29 |
2012-06-19 |
Amarin Corp Plc |
Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
|
|
AR077208A1
(es)
|
2009-06-30 |
2011-08-10 |
Lilly Co Eli |
Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
|
|
US20110004011A1
(en)
|
2009-07-01 |
2011-01-06 |
Declan Costello |
Novel process
|
|
JP2012533560A
(ja)
|
2009-07-15 |
2012-12-27 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
細胞における取り込みが制御可能なペプチド
|
|
EP2556159A1
(en)
|
2010-04-07 |
2013-02-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cetp expression
|
|
US20130197226A1
(en)
*
|
2010-07-28 |
2013-08-01 |
Jean-Claude Tardif |
Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
|
|
BR112013004557A2
(pt)
|
2010-09-16 |
2016-09-06 |
Hoffmann La Roche |
novo processo.
|
|
PE20140018A1
(es)
|
2010-11-04 |
2014-01-31 |
Hoffmann La Roche |
Una composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica
|
|
WO2012069087A1
(en)
|
2010-11-25 |
2012-05-31 |
Mediasuccess Gmbh |
Automatic text generation
|
|
WO2012076443A1
(en)
|
2010-12-08 |
2012-06-14 |
F. Hoffmann-La Roche Ag |
Liposomal formulation of dalcetrapib
|
|
TR201818880T4
(tr)
|
2010-12-16 |
2019-01-21 |
Hoffmann La Roche |
Disülfürlerin hidrojenasyonu yoluyla aromatik tiyol türevlerinin hazırlanması prosesi.
|
|
US20140044668A1
(en)
*
|
2011-02-15 |
2014-02-13 |
The Ohio State University |
Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs
|
|
BR112013021030A2
(pt)
|
2011-02-17 |
2016-10-11 |
Hoffmann La Roche |
processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente
|
|
US9541565B2
(en)
|
2011-04-08 |
2017-01-10 |
Zora Biosciences Oy |
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
JP5980900B2
(ja)
|
2011-04-08 |
2016-08-31 |
ゾラ バイオサイエンシーズ オサケ ユキチュア |
スタチン誘発性筋毒性の高感度検出のためのバイオマーカー
|
|
WO2012149473A2
(en)
*
|
2011-04-29 |
2012-11-01 |
Children's Hospital & Research Center At Oakland |
Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
|
|
US20120301439A1
(en)
|
2011-05-24 |
2012-11-29 |
Washington University |
Inhibition of choroidal neovascularization
|
|
US8975438B2
(en)
|
2011-07-13 |
2015-03-10 |
Hoffmann-La Roche Inc. |
Process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
AR089853A1
(es)
|
2012-02-01 |
2014-09-24 |
Boehringer Ingelheim Int |
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
|
|
JP6080226B2
(ja)
|
2012-03-06 |
2017-02-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
|
|
EP2844245A1
(en)
|
2012-04-30 |
2015-03-11 |
F. Hoffmann-La Roche AG |
New formulation
|
|
MX351059B
(es)
|
2012-08-17 |
2017-09-29 |
Laboratorios Senosiain S A De C V Star |
Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
|
|
WO2014154606A1
(en)
|
2013-03-27 |
2014-10-02 |
F. Hoffmann-La Roche Ag |
Genetic markers for predicting responsiveness to therapy
|
|
JP6539661B2
(ja)
|
2013-12-19 |
2019-07-03 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
眼疾患の処置において使用するためのｃｅｔｐモデュレーター
|
|
GB201401617D0
(en)
*
|
2014-01-30 |
2014-03-19 |
Helperby Therapeutics Ltd |
Novel combination and use
|
|
WO2016016157A1
(en)
|
2014-07-30 |
2016-02-04 |
F. Hoffmann-La Roche Ag |
Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
|
|
WO2019043018A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND REDUCING THE RISK OF CARDIOVASCULAR EVENTS
|
|
BR112021002387A2
(pt)
|
2018-08-09 |
2021-05-11 |
Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch |
métodos para retardo de ocorrência de diabetes tipo 2 de início recente e para redução da progressão e tratamento de diabetes tipo 2
|